ArticleHead & neck2026
External Validation of Pre-Treatment Primary Tumor Volume as a Prognostic Factor in Head and Neck Cancer Treated With (Chemo)Radiotherapy.
Article in Head & neck, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPrimary tumor volume (GTVp) is a key prognostic factor in oropharyngeal squamous cell carcinoma (OPSCC) treated with radiotherapy. We aimed to externally validate this association and assess its relevance in other head and neck sites.
methodsPatients from the RADCURE dataset were analyzed using Cox regression for local failure, progression-free survival (PFS), and overall survival (OS). Subgroup analyses included HPV status, chemotherapy use, and separate evaluations for hypopharyngeal and laryngeal cancers. Model performance was assessed using the concordance index (C-index).
resultsAmong 1286 OPSCC patients, increasing GTVp was associated with a higher risk of local failure and reduced PFS and OS, consistent across HPV and chemotherapy subgroups. Similar associations were observed in hypopharyngeal (n = 157) and laryngeal (n = 803) cancers. Model performance was strong (C-index up to 0.82).
conclusionPrimary tumor volume is a robust prognostic factor across head and neck cancer sites, supporting risk stratification in curative radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.